Taiwan · Delayed Price · Currency is TWD Pharmigene Statistics
Total Valuation
Pharmigene has a market cap or net worth of TWD 353.26 million. The enterprise value is 897.12 million.
| Market Cap | 353.26M |
| Enterprise Value | 897.12M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmigene has 50.47 million shares outstanding. The number of shares has decreased by -0.10% in one year.
| Current Share Class | 50.47M |
| Shares Outstanding | 50.47M |
| Shares Change (YoY) | -0.10% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.13% |
| Owned by Institutions (%) | n/a |
| Float | 29.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.88 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 2.45.
| Current Ratio | 1.91 |
| Quick Ratio | 1.41 |
| Debt / Equity | 2.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | -99.79 |
| Interest Coverage | -3.11 |
Financial Efficiency
Return on equity (ROE) is -18.32% and return on invested capital (ROIC) is -3.07%.
| Return on Equity (ROE) | -18.32% |
| Return on Assets (ROA) | -2.97% |
| Return on Invested Capital (ROIC) | -3.07% |
| Return on Capital Employed (ROCE) | -5.32% |
| Weighted Average Cost of Capital (WACC) | 2.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 42 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 3.23 |
Taxes
In the past 12 months, Pharmigene has paid 3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.09% in the last 52 weeks. The beta is 0.00, so Pharmigene's price volatility has been lower than the market average.
| Beta (5Y) | 0.00 |
| 52-Week Price Change | -33.09% |
| 50-Day Moving Average | 7.28 |
| 200-Day Moving Average | 9.47 |
| Relative Strength Index (RSI) | 52.68 |
| Average Volume (20 Days) | 29,316 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmigene had revenue of TWD 187.88 million and -52.27 million in losses. Loss per share was -1.04.
| Revenue | 187.88M |
| Gross Profit | 52.63M |
| Operating Income | -44.82M |
| Pretax Income | -52.26M |
| Net Income | -52.27M |
| EBITDA | -25.47M |
| EBIT | -44.82M |
| Loss Per Share | -1.04 |
Balance Sheet
The company has 92.58 million in cash and 636.45 million in debt, with a net cash position of -543.86 million or -10.78 per share.
| Cash & Cash Equivalents | 92.58M |
| Total Debt | 636.45M |
| Net Cash | -543.86M |
| Net Cash Per Share | -10.78 |
| Equity (Book Value) | 260.29M |
| Book Value Per Share | 5.18 |
| Working Capital | 71.56M |
Cash Flow
In the last 12 months, operating cash flow was -4.14 million and capital expenditures -2.23 million, giving a free cash flow of -6.38 million.
| Operating Cash Flow | -4.14M |
| Capital Expenditures | -2.23M |
| Depreciation & Amortization | 19.35M |
| Net Borrowing | 17.13M |
| Free Cash Flow | -6.38M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 28.01%, with operating and profit margins of -23.86% and -27.82%.
| Gross Margin | 28.01% |
| Operating Margin | -23.86% |
| Pretax Margin | -27.82% |
| Profit Margin | -27.82% |
| EBITDA Margin | -13.56% |
| EBIT Margin | -23.86% |
| FCF Margin | n/a |
Dividends & Yields
Pharmigene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.10% |
| Shareholder Yield | 0.10% |
| Earnings Yield | -14.80% |
| FCF Yield | -1.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |